EXPONENT, INC.
At today's price, EXPONENT, INC. (EXPO) is priced for +18.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Exponent is a specialist engineering and scientific consultancy of roughly a thousand PhD-level experts called in for failure analysis, litigation support, and regulatory work, earning a return on equity in the low thirties with no net debt and pricing power that lets it raise billing rates. • The central risk is valuation versus trajectory: the price pays about 23 times operating income and needs roughly 18.6% annual operating-profit growth for several years, while fiscal 2025 operating incom
Is EXPO overvalued? See what's priced in →
348 institutional managers reported holding EXPO in 13F filings for the quarter ended 2026-03-31. Together they hold about 95% of the company; the top 10 hold 52%. 47 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 2.7M shares were sold short as of the 2026-06-15 count, about 5% of shares outstanding (4.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
EXPO has cut its share count 5.4% over the past five years, spending $362.34M on repurchases. It pays a dividend, and has for 13 years running; the current rate is $1.20 a share annually. Cash returned over the past three years: $162.66M in dividends and $206.49M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at EXPO over the trailing three years. Absence is a fact about the company, not a signal. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
EXPO's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-08 | -6.3% | +3.7% |
| 2023-11-04 | -12.3% | +15.1% |
| 2024-02-24 | +1.0% | +21.1% |
| 2024-05-04 | +18.3% | -0.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
EXPO's latest 8-K filings: 2026-06-10 (items 5.07); 2026-04-30 (items 2.02, 7.01, 9.01); 2026-04-06 (items 5.02, 9.01); 2026-02-05 (items 2.02, 7.01, 9.01); 2025-10-30 (items 2.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 29, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.